Globe Life Inc. (NYSE:GL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Globe Life Inc. (NYSE:GL) has been assigned an average rating of “Moderate Buy” from the eleven research firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $171.3333.

Several research analysts have issued reports on the stock. Wells Fargo & Company lifted their price target on shares of Globe Life from $170.00 to $171.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. raised their price objective on Globe Life from $180.00 to $181.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. TD Cowen restated a “buy” rating on shares of Globe Life in a report on Thursday, December 11th. Truist Financial boosted their target price on Globe Life from $158.00 to $180.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Finally, Weiss Ratings raised Globe Life from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, February 13th.

Insider Activity at Globe Life

In other Globe Life news, EVP Robert Edward Hensley sold 712 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $142.59, for a total value of $101,524.08. Following the completion of the transaction, the executive vice president directly owned 8,580 shares in the company, valued at $1,223,422.20. This trade represents a 7.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO James Matthew Darden sold 18,318 shares of Globe Life stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $145.10, for a total transaction of $2,657,941.80. Following the completion of the transaction, the chief executive officer directly owned 51,093 shares in the company, valued at approximately $7,413,594.30. This trade represents a 26.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 82,807 shares of company stock valued at $12,041,286. Corporate insiders own 1.51% of the company’s stock.

Institutional Trading of Globe Life

Large investors have recently added to or reduced their stakes in the company. Allianz Asset Management GmbH increased its holdings in shares of Globe Life by 55.2% in the 3rd quarter. Allianz Asset Management GmbH now owns 82,263 shares of the company’s stock valued at $11,761,000 after purchasing an additional 29,256 shares during the period. Synergy Asset Management LLC boosted its holdings in shares of Globe Life by 1,022.7% during the third quarter. Synergy Asset Management LLC now owns 100,603 shares of the company’s stock worth $14,240,000 after purchasing an additional 91,642 shares during the period. Retirement Systems of Alabama acquired a new stake in shares of Globe Life during the third quarter worth approximately $2,470,000. SteelPeak Wealth LLC purchased a new position in Globe Life during the third quarter valued at approximately $2,985,000. Finally, Pzena Investment Management LLC increased its stake in Globe Life by 5.6% in the 3rd quarter. Pzena Investment Management LLC now owns 998,506 shares of the company’s stock valued at $142,756,000 after buying an additional 52,523 shares during the period. 81.61% of the stock is owned by institutional investors and hedge funds.

Globe Life Stock Performance

NYSE:GL opened at $137.56 on Thursday. The company has a 50-day moving average of $141.54 and a 200-day moving average of $138.89. The firm has a market cap of $10.79 billion, a price-to-earnings ratio of 9.77 and a beta of 0.46. The company has a current ratio of 0.07, a quick ratio of 0.07 and a debt-to-equity ratio of 0.39. Globe Life has a twelve month low of $109.38 and a twelve month high of $152.71.

Globe Life (NYSE:GL) last released its earnings results on Wednesday, February 4th. The company reported $3.39 EPS for the quarter, missing analysts’ consensus estimates of $3.44 by ($0.05). Globe Life had a return on equity of 21.30% and a net margin of 19.37%.The business had revenue of $1.52 billion during the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the previous year, the firm earned $3.14 earnings per share. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. Globe Life has set its FY 2026 guidance at 14.950-15.650 EPS. Analysts forecast that Globe Life will post 13.87 earnings per share for the current fiscal year.

Globe Life Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Friday, April 3rd will be issued a dividend of $0.33 per share. This represents a $1.32 annualized dividend and a yield of 1.0%. The ex-dividend date is Thursday, April 2nd. This is a boost from Globe Life’s previous quarterly dividend of $0.27. Globe Life’s dividend payout ratio is presently 7.67%.

Globe Life Company Profile

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.